Exciting news in oncology! A recent study suggests that combo therapy (likely combining chemotherapy with other treatments like immunotherapy or targeted therapy) may reduce the risk of recurrence and death in stage 3 colon cancer by up to 50% compared to standard treatments alone.

Key Points:

• Stage 3 colon cancer means the cancer has spread to nearby lymph nodes but not distant organs.
• Current standard treatment is surgery + chemotherapy (e.g., FOLFOX or CAPOX).
• The new combo therapy (exact drugs not specified here) appears to significantly improve outcomes.
• A 50% reduction in recurrence and death risk is a major breakthrough if confirmed in larger trials.

Why This Matters:

• Colon cancer recurrence is a major concern; preventing it improves survival.
• If validated, this could become a new standard of care for high-risk patients.

Reference:

https://www.targetedonc.com/view/atezolizumab-chemo-reduces-risk-of-recurrence-or-death-by-50-in-dmmr-colon-cancer

https://www.medicalnewstoday.com/articles/combo-immunotherapy-may-cut-stage-3-colon-cancer-recurrence-death-rate-50-percent

https://newsnetwork.mayoclinic.org/discussion/immunotherapy-boosts-chemotherapy-in-combating-stage-3-colon-cancer

https://pmc.ncbi.nlm.nih.gov/articles/PMC3126021

Medications that have been suggested by doctors worldwide are available on below link

https://mygenericpharmacy.com/category/disease/cancer